Tue. 7 May 2024, 4:49pm ET
Benzinga
Earnings, Earnings Beats, News
Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 28.57 percent increase over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $1.25 million which beat the analyst consensus estimate of $760.00 thousand by 64.74 percent. This is a 38.87 percent decrease over sales of $2.05 million the same period last year.